Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Vertex Pharmaceuticals Incorporated (VRTX) — XLV Health Care · S&P 500 Profile |福泰製藥公司介紹

health-careS&P500xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Vertex Pharmaceuticals Incorporated (VRTX) — Business, History & S&P 500 Profile |福泰製藥公司介紹

Vertex Pharmaceuticals company profile · cystic fibrosis & precision medicines · history · financial snapshot · S&P 500 rank #87 · 福泰製藥公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 29, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$136.87B
Oct 29, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.19%
Rank #87 · Oct 29, 2026 (Slickcharts)
FY2025 TOTAL REVENUES
$12.00B
+9% YoY · product revenues $11.97B
FY2025 NET INCOME
$3.95B
Diluted EPS $15.32 · vs FY2024 loss

SNAPSHOT

TickerVRTX (NASDAQ)
CompanyVertex Pharmaceuticals Incorporated
GICS sector / industryHealth Care (XLV) / Biotechnology
S&P 500 rank (by weight)#87 · 0.19% (Oct 29, 2026)
Sector rank (by market cap)#13 in Health Care (Oct 29, 2026)
Share price (frozen benchmark)$540.00 (Oct 29, 2026)
HeadquartersBoston, Massachusetts
Founded1989
CEOReshma Kewalramani (since April 2020)
Employees≈6,400 (2025)
Market cap$136.87B (Oct 29, 2026)
SEC filingsSEC EDGAR — Vertex Pharmaceuticals Incorporated filings (company search)

WHAT IT DOES

Vertex Pharmaceuticals is a biotechnology company that discovers, develops and sells precision medicines for serious diseases, built on a dominant cystic fibrosis franchise. FY2025 total revenues were $12.00B, up 9%, of which product revenues were $11.97B.

The cystic fibrosis franchise is the engine: TRIKAFTA/KAFTRIO alone produced $10.31B in FY2025, and the successor ALYFTREK, launched in late 2024, added $0.84B as patients transition to the once-daily regimen. Beyond cystic fibrosis, the company is commercializing CASGEVY, the first CRISPR-based gene-editing therapy, and JOURNAVX, a non-opioid medicine for acute pain.

Vertex reports as a single operating segment, so the revenue story is a product story: one disease area funds a pipeline spanning kidney disease, pain, diabetes and blood disorders, with research spending to match. GAAP operating income recovered to $4.17B in FY2025 after a loss-making FY2024 that carried heavy acquired-research charges.

PRODUCT REVENUES — FY2025

SegmentRevenueShareYoY
TRIKAFTA/KAFTRIO$10.31B85.9%+0.7%
ALYFTREK$0.84B7.0%—
Other product revenues$0.82B6.8%+5%
Other revenues$0.03B0.3%—
Total revenues$12.00B100%+9%
Source: Vertex fourth-quarter and full-year 2025 results release. The company reports as a single operating segment; the table breaks out product revenues, which sum with other revenues to total revenues. ALYFTREK had no FY2024 revenue, so no year-on-year rate is shown.

HISTORY

YearMilestone
1989Founded in Cambridge, Massachusetts, by Joshua Boger and colleagues to pursue structure-based drug design
1995Lists its shares publicly
1999Agenerase, its first marketed medicine, is approved for HIV
2011Incivek (telaprevir) is approved for hepatitis C, a commercial breakthrough later withdrawn as treatment advanced
2012Kalydeco (ivacaftor) is approved, the first medicine to treat the underlying cause of cystic fibrosis
2015Orkambi is approved, extending cystic fibrosis treatment to the most common mutation combination
2018Symdeko is approved, adding a further cystic fibrosis combination regimen
2019Trikafta is approved, a triple combination that transforms cystic fibrosis care for most patients
2020Reshma Kewalramani becomes chief executive officer in April 2020
2023Casgevy is approved, the first CRISPR-based gene-editing therapy, developed with CRISPR Therapeutics
2024Alyftrek is approved in December 2024 as the once-daily successor to Trikafta
2025Journavx is approved in January 2025 as a non-opioid treatment for acute pain; total revenues reach $12.00B

COMPETITIVE POSITION

  • Cystic fibrosis monopoly in practice — no rival matches the breadth of Vertex’s cystic fibrosis portfolio, and the switch to Alyftrek extends exclusivity into the next decade.
  • Pricing power with payer friction — life-changing cystic fibrosis medicines command premium prices, but access negotiations and pricing pressure recur in every market.
  • Pipeline optionality — Casgevy, Journavx and kidney-disease candidates diversify away from cystic fibrosis, though none yet approaches the core franchise in scale.
  • Manufacturing complexity — cell and gene therapies cost more to make and deliver than small-molecule pills, slowing uptake and squeezing margins on the new launches.
  • Competition set — other rare-disease and pain developers, plus large biopharma, contest the same pipeline areas, while generic pressure awaits patent expiry on the older combinations.

FINANCIAL SNAPSHOT — FY2025

Total revenues$12.00B (+9% YoY)
Product revenues, net$11.97B
Cost of sales$1.65B
Operating income (GAAP)$4.17B
Net income$3.95B
Diluted EPS$15.32 (vs a loss in FY2024)
Total assets$25.64B (Dec 31, 2025)
Cash and short-term investments$6.61B (Dec 31, 2025)
Source: Vertex fourth-quarter and full-year 2025 results release (February 2026) and FY2025 Form 10-K. FY2024 reported a net loss of $0.54B, including acquired in-process research and development charges, so year-on-year earnings comparisons are not meaningful on a GAAP basis.

KEY RISKS

  • Single-franchise concentration — cystic fibrosis products produce nearly all revenue, so a safety issue, pricing defeat or competitive breakthrough would hit the whole company.
  • Trikafta maturity — Trikafta growth slowed to 0.7% in FY2025; the franchise now depends on converting patients to Alyftrek before patents expire.
  • Pipeline failure — kidney, pain and diabetes candidates can fail in late-stage trials after years of research spending.
  • Gene-therapy execution — Casgevy’s complex manufacturing and treatment-center capacity limit how fast uptake can grow.
  • Pricing and access politics — premium drug prices face payer pushback, government negotiation and public scrutiny in the United States and Europe.

WHY IT MATTERS FOR THE S&P 500

Vertex is the S&P 500’s cystic-fibrosis pure play: at a 0.19% index weight and the #13 market cap in Health Care, it is the index’s main exposure to rare-disease pricing power and precision-medicine economics.

Its product revenues are a standing read on rare-disease adoption — Trikafta-to-Alyftrek conversion, Casgevy uptake and Journavx launch progress show up here before they show up in sector aggregates.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Oct 29, 2026 close)
FinancialsVertex FY2025 Form 10-K (SEC EDGAR) and fourth-quarter/full-year 2025 results release (February 2026)
Sector classificationGICS (Biotechnology) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

VRTX

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼VRTX(NASDAQ)
公司Vertex Pharmaceuticals Incorporated
GICS 板塊/行業醫療保健(XLV)/生物科技
標普500排名(按權重)#87 · 0.19%(2026 年 10 月 29 日)
板塊內排名(按市值)醫療保健第 #13(2026 年 10 月 29 日)
股價(凍結基準)$540.00(2026 年 10 月 29 日)
總部美國麻省波士頓
成立1989 年
行政總裁Reshma Kewalramani(自 2020 年 4 月)
員工≈6,400(2025 年)
市值$136.87B(2026 年 10 月 29 日)
SEC 申報SEC EDGAR — Vertex Pharmaceuticals Incorporated 申報(公司檢索)

業務概覽

福泰製藥是一家生物科技公司,研發並銷售針對嚴重疾病的精準藥物,基礎是佔主導地位的囊性纖維化業務。FY2025 總收入為 $12.00B,同比增長 9%,其中產品收入為 $11.97B。

囊性纖維化業務是引擎:TRIKAFTA/KAFTRIO 在 FY2025 單獨貢獻 $10.31B,2024 年底上市的後續藥物 ALYFTREK 隨著患者轉用每日一次方案,新增 $0.84B。囊性纖維化以外,公司正在商業化首個 CRISPR 基因編輯療法 CASGEVY,以及非阿片類急性止痛藥 JOURNAVX。

福泰以單一經營板塊申報,因此收入故事即產品故事:一個疾病領域資助著涵蓋腎病、疼痛、糖尿病與血液疾病的管線,研發投入與之匹配。GAAP 營業利潤在 FY2025 恢復至 $4.17B,而 FY2024 因沉重的收購研發支出而虧損。

產品收入 — FY2025

板塊收入佔比同比
TRIKAFTA/KAFTRIO$10.31B85.9%+0.7%
ALYFTREK$0.84B7.0%—
其他產品收入$0.82B6.8%+5%
其他收入$0.03B0.3%—
總收入$12.00B100%+9%
來源:福泰 2025 年第四季度及全年業績發佈。公司以單一經營板塊申報;本表拆分產品收入,連同其他收入合計即為總收入。ALYFTREK 在 FY2024 並無收入,故不列同比。

歷史沿革

年份里程碑
1989由 Joshua Boger 等人在麻省劍橋創立,從事基於結構的藥物設計
1995股份公開上市
1999首個上市藥物 Agenerase 獲批,用於治療愛滋病
2011Incivek(telaprevir)獲批治療丙型肝炎,商業上取得突破,後因療法進步而撤市
2012Kalydeco(ivacaftor)獲批,首個針對囊性纖維化根本病因的藥物
2015Orkambi 獲批,將囊性纖維化治療擴展至最常見的突變組合
2018Symdeko 獲批,增加一種囊性纖維化聯合方案
2019Trikafta 獲批,三聯組合改變了大多數患者的囊性纖維化治療
2020Reshma Kewalramani 於 2020 年 4 月出任行政總裁
2023Casgevy 獲批,為首個 CRISPR 基因編輯療法,與 CRISPR Therapeutics 共同研發
2024Alyftrek 於 2024 年 12 月獲批,作為 Trikafta 的每日一次後續藥物
2025Journavx 於 2025 年 1 月獲批,為非阿片類急性止痛藥;總收入達 $12.00B

競爭地位

  • 實際上的囊性纖維化壟斷——沒有對手能匹敵福泰囊性纖維化組合的廣度,轉用 Alyftrek 更將獨佔期延至下一個十年。
  • 定價能力與付款方摩擦——改變生命的囊性纖維化藥物享有溢價,但每個市場的准入談判與定價壓力反覆出現。
  • 管線選擇權——Casgevy、Journavx 與腎病候選藥物令業務分散於囊性纖維化之外,但規模上無一接近核心業務。
  • 製造複雜度——細胞與基因療法的製造與交付成本高於小分子藥片,拖慢新產品採用並壓縮利潤率。
  • 競爭集合——其他罕見病與疼痛藥物開發商及大型生物製藥公司爭奪同一管線領域,而舊聯合藥物專利到期後將面臨仿製藥壓力。

財務快照 — FY2025

總收入$12.00B(同比 +9%)
產品收入(淨額)$11.97B
銷售成本$1.65B
營業利潤(GAAP)$4.17B
淨利潤$3.95B
攤薄每股盈利$15.32(FY2024 為虧損)
總資產$25.64B(2025 年 12 月 31 日)
現金及短期投資$6.61B(2025 年 12 月 31 日)
來源:福泰 2025 年第四季度及全年業績發佈(2026 年 2 月)與 FY2025 Form 10-K。FY2024 錄得淨虧損 $0.54B,含收購在研項目支出,故 GAAP 口徑的盈利同比比較意義不大。

主要風險

  • 單一業務集中——囊性纖維化產品貢獻幾乎全部收入,安全問題、定價失利或競爭突破都會衝擊整家公司。
  • Trikafta 成熟——Trikafta 在 FY2025 增長放緩至 0.7%,業務現取決於專利到期前將患者轉用 Alyftrek。
  • 管線失敗——腎病、疼痛與糖尿病候選藥物可在多年研發投入後於後期試驗失敗。
  • 基因療法執行——Casgevy 複雜的製造與治療中心容量,限制了採用增長速度。
  • 定價與准入政治——高價藥物在美國與歐洲面臨付款方抵制、政府議價與公眾審視。

對標普500的重要性

福泰是標普500中純粹的囊性纖維化標的:指數權重 0.19%、醫療保健板塊市值第 #13,是指數對罕見病定價能力與精準醫療經濟的主要敞口。

其產品收入是罕見病採用的常設讀數——Trikafta 向 Alyftrek 的轉換、Casgevy 的採用與 Journavx 的上市進展,往往先在此反映,再體現於板塊總數。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 29 日收盤)
財務福泰 FY2025 Form 10-K(SEC EDGAR)及 2025 年第四季度/全年業績發佈(2026 年 2 月)
板塊分類GICS(生物科技),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

VRTX

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · VRTX
Data as of Oct 29, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · The Boeing Company (BA) — XLI Industrials · S&P 500 Profile |波音公司介紹Next · Chubb Limited (CB) — XLF Financials · S&P 500 Profile |安達有限公司介紹

Entered 2026-10-30 04:53 · updated 2026-11-15 00:14 · rev 7